Stem Cell Culture Patents: Who Leads, Where the Gaps Are 2026
Stem cell perfusion culture patents: concentration, momentum and where filing has gone quiet
Filing peaked in 2021 at 20 records, then fell sharply the tracked span shows 20 filings in 2021 dropping to 1 by 2024, a -95% swing that predates the usual 18-month publication lag. Filings climbed to a peak of 20 in 2021 before declining to 1 by 2024, a -95% drop over that three-year span. Because publication lags filing by around 18 months, 2025 and 2026 figures are still filling in and should not be read as confirmation the field has cooled — only 2021-2024 is a safe comparison window.
- 1THE GENERAL HOSPITAL CORP44
- 2THE RGT UNIV OF MICHIGAN27
- 3VIACYTE INC25
- 4FUJIFILM CELLULAR DYNAMICS INC17
- 5INSCEPTION BIOSCI12
See the full stem cell culture perfusion culture analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents in perfusion-based stem cell culture?
One assignee leads with 44 of the 245 records in scope, well ahead of the field. The top 5 assignees combine for 51.0% of all records and the top 10 reach 66.5%, so ownership is concentrated in a narrow band of academic medical centres and one perfusion-focused biotech rather than spread evenly across the 73 ranked assignees. Anyone entering this space should expect to negotiate around or design around that leading portfolio first.
Is patent filing in stem cell perfusion culture growing or shrinking?
Filings peaked at 20 in 2021 and had fallen to 1 by 2024, a -95% change across that complete-year window. Because patent publication lags filing by roughly 18 months, the 2025 and 2026 figures in any dataset are still incomplete and should not be read as proof the field has kept declining. The safest read is that filing activity cooled markedly after 2021 based on the years that are fully counted.
What technology areas are most heavily claimed in this field?
C12N, covering microorganisms and genetic engineering techniques, appears in 94.3% of the 245 records in scope, making it the densest single class. A61K (medicinal preparations) follows at 44.1% and C12M (bioreactors and apparatus) at 34.7%, with sterilising and disinfecting art (A61L) the thinnest at 5.7%. A record can carry more than one class, so these figures overlap rather than sum to 100%.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Stem Cell Culture Perfusion Culture covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.